Safety and Efficacy of APD356 in the Treatment of Obesity

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c receptor agonist, in clinical development as a potential treatment for obesity.

The purpose of this study is to obtain preliminary assessment of the safety and efficacy of APD356, when administered daily for 28 days, in obese subjects who are otherwise healthy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Arena Pharmaceuticals; Eisai Inc.

Criteria

• Healthy male or nonpregnant, nonlactating females aged between 18 and 65 years (inclusive)

• Body Mass Index (BMI) of 30-45 Kg/m^2.

• Non-smoker

• No concomitant medications

• No past treatment with drugs associated with the development of pulmonary hypertension or cardiac valvular insufficiency